Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype

[1]  Laura H. Tang,et al.  Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild‐type BRCA pancreatic ductal adenocarcinoma , 2018, Cancer.

[2]  Laura H. Tang,et al.  Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. , 2018, European journal of cancer.

[3]  J. Iovanna,et al.  Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts , 2017, Cell reports.

[4]  Noam Shental,et al.  Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine , 2017, Science.

[5]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. , 2017, Cancer cell.

[6]  J. Tabernero,et al.  Pancreatic cancer heterogeneity and response to Mek inhibition , 2017, Oncogene.

[7]  E. Giovannetti,et al.  Drug resistance in pancreatic cancer: Impact of altered energy metabolism. , 2017, Critical reviews in oncology/hematology.

[8]  D. Gilot,et al.  Definition and identification of small RNA sponges: Focus on miRNA sequestration. , 2017, Methods.

[9]  J. Qi,et al.  Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts , 2017, EMBO molecular medicine.

[10]  Mohammad Aslam Khan,et al.  Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK , 2017, British Journal of Cancer.

[11]  R. Hill,et al.  CANCER-ASSOCIATED FIBROBLAST EXOSOMES REGULATE SURVIVAL AND PROLIFERATION OF PANCREATIC CANCER CELLS , 2016, Oncogene.

[12]  Rong Liu,et al.  Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis , 2016, Cancer Chemotherapy and Pharmacology.

[13]  Lizhou Lin,et al.  Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer , 2016, Tumor Biology.

[14]  Gordon B Mills,et al.  Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. , 2016, Cell reports.

[15]  J. Iovanna,et al.  A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT , 2016, Oncotarget.

[16]  M. Basson,et al.  P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer , 2016, Oncotarget.

[17]  Wei Li,et al.  Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling , 2016, Oncogene.

[18]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[19]  J. Winter,et al.  The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms , 2016, International journal of biological sciences.

[20]  R. Holcombe,et al.  Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer , 2016, Clinical Cancer Research.

[21]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[22]  A. Krasinskas,et al.  A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas , 2015, The American journal of surgical pathology.

[23]  Jen Jen Yeh,et al.  Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma , 2015, Nature Genetics.

[24]  J. Mann,et al.  The role of pancreatic stellate cells in pancreatic cancer. , 2015, Surgical oncology.

[25]  Jingwu Xie,et al.  Promising molecular mechanisms responsible for gemcitabine resistance in cancer , 2015, Genes & diseases.

[26]  Menghong Sun,et al.  MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine , 2015, Oncotarget.

[27]  J. Iovanna,et al.  Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. , 2015, The American journal of pathology.

[28]  Yinxue Wang,et al.  The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer , 2015, Journal of Translational Medicine.

[29]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[30]  Caroline H. Diep,et al.  Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer , 2015, Clinical Cancer Research.

[31]  G. Blandino,et al.  Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. , 2015, Biochimica et biophysica acta.

[32]  R. Jesenofsky,et al.  Desmoplasia and Chemoresistance in Pancreatic Cancer , 2014, Cancers.

[33]  L. You,et al.  MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis , 2014, Oncotarget.

[34]  E. Giovannetti,et al.  miR-211 Modulates Gemcitabine Activity Through Downregulation of Ribonucleotide Reductase and Inhibits the Invasive Behavior of Pancreatic Cancer Cells , 2014, Nucleosides, nucleotides & nucleic acids.

[35]  Jean-Paul Borg,et al.  Identification of new mechanisms of cellular response to chemotherapy by tracking changes in post-translational modifications by ubiquitin and ubiquitin-like proteins. , 2014, Journal of proteome research.

[36]  F. Sipos,et al.  Intratumoral functional heterogeneity and chemotherapy. , 2014, World journal of gastroenterology.

[37]  H. Friess,et al.  The role of inflammation in pancreatic cancer. , 2014, Advances in experimental medicine and biology.

[38]  Peter Vaupel,et al.  Hypoxia in tumors: pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications. , 2014, Advances in experimental medicine and biology.

[39]  M. Amit,et al.  Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase , 2013, Oncoimmunology.

[40]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[41]  S. Pandol,et al.  A starring role for stellate cells in the pancreatic cancer microenvironment. , 2013, Gastroenterology.

[42]  Y. Miao,et al.  miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. , 2013, Oncology reports.

[43]  D. Aust,et al.  WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer. , 2013, Neoplasia.

[44]  H. Shepard,et al.  Therapeutic Targeting of Hyaluronan in the Tumor Stroma , 2012, Cancers.

[45]  G. Colucci,et al.  Conventional chemotherapy of advanced pancreatic cancer. , 2012, Current Drug Targets.

[46]  Thomas Helleday,et al.  The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings , 2011, Molecular oncology.

[47]  J. Izbicki,et al.  Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. , 2011, Cancer research.

[48]  A. Masamune,et al.  Pancreatic stellate cells radioprotect pancreatic cancer cells through β1-integrin signaling. , 2011, Cancer research.

[49]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[50]  P. Spellman,et al.  Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy , 2011, Nature Medicine.

[51]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[52]  R. Qin,et al.  Pancreatic Cancer Cells Resistant to Chemoradiotherapy Rich in “Stem-Cell-Like” Tumor Cells , 2011, Digestive Diseases and Sciences.

[53]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[54]  R. Singal,et al.  Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity. , 2010, Anticancer research.

[55]  T. Keck,et al.  ZEB1 in Pancreatic Cancer , 2010, Cancers.

[56]  Tibor Schuster,et al.  Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages , 2010, PLoS medicine.

[57]  F. Bertucci,et al.  Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model , 2010, PloS one.

[58]  Huamin Wang,et al.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. , 2009, Cancer research.

[59]  Zhiwei Wang,et al.  3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. , 2009, Cancer research.

[60]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[61]  K. Ohuchida,et al.  MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance , 2009, Molecular Cancer Therapeutics.

[62]  Zhiwei Wang,et al.  Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. , 2009, Cancer research.

[63]  M. Goto,et al.  Precursor lesions of pancreatic cancer. , 2008, Gut and liver.

[64]  T. Gress,et al.  Pancreatic Intraepithelial Neoplasia Revisited and Updated , 2008, Pancreatology.

[65]  A. Maitra,et al.  Pancreatic Carcinogenesis , 2008, Pancreatology.

[66]  Richard P. Hill,et al.  Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability , 2008, Nature Reviews Cancer.

[67]  C. Heeschen,et al.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.

[68]  R. Hruban,et al.  Molecular genetics of pancreatic intraepithelial neoplasia. , 2007, Journal of hepato-biliary-pancreatic surgery.

[69]  G. Semenza,et al.  HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. , 2007, Cancer cell.

[70]  F. Meyskens,et al.  UC Irvine UC Irvine Previously Published Works Title Reactive oxygen species : a breath of life or death ? , 2007 .

[71]  E. Tiligada.  Chemotherapy: induction of stress responses. , 2006, Endocrine-related cancer.

[72]  H. Friess,et al.  Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. , 2006, The Journal of surgical research.

[73]  A. Rajasekaran,et al.  Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. , 2006, Cancer research.

[74]  K. Tsuchida,et al.  Tumor-Stroma Interaction of Human Pancreatic Cancer: Acquired Resistance to Anticancer Drugs and Proliferation Regulation Is Dependent on Extracellular Matrix Proteins , 2004, Pancreas.

[75]  B. Aggarwal,et al.  Nuclear factor-kappa B and cancer: its role in prevention and therapy. , 2002, Biochemical pharmacology.

[76]  Michael C. Montalto,et al.  Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. , 2002, Cancer research.

[77]  M. Tsao,et al.  Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. , 2000, Cancer research.

[78]  J. Cameron,et al.  Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. , 2000, The American journal of pathology.

[79]  R. Raghow.  Role of transforming growth factor-beta in repair and fibrosis. , 1991, Chest.

[80]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.